VASCULAR THROBOSIS VASCULAR THROBOSIS PREVENTION IN ARTERY PREVENTION IN ARTERY

SURGERYSURGERY

• P. NiedzielaP. Niedziela J. MichalakJ. Michalak W. Kobusiewicz W. Kobusiewicz,,

Department of Vascular Surgery Medical Academy, Lublin, PolandDepartment of Vascular Surgery Medical Academy, Lublin, Poland

PRAGUE 2002PRAGUE 2002

thrombosis in case thrombosis in case

obesityobesity

age above 40 age above 40

malignant cancersmalignant cancers

hormonal drughormonal drug

varicose veins varicose veins

< 1 hours< 1 hours 57 %57 %

1 – 3 1 – 3 hourshours 35 %35 %

> 3 hours> 3 hours 8 %8 %

methodsmethods

physicalphysicalpharmacologicalpharmacological

Standard heparinStandard heparin

LMWHLMWH

DextranDextran

Oral anticoagulantsOral anticoagulants

Acetylsalicylic acidAcetylsalicylic acid

low risklow risk

medium riskmedium risk

high riskhigh risk

age up 40age up 40

have undergone operative treatmentshave undergone operative treatments

without clinical risk factorswithout clinical risk factors

more than 40 years oldmore than 40 years old

major arterial treatmentsmajor arterial treatments

without clinical risk factors without clinical risk factors

above 40 years oldabove 40 years old

vast reconstructive operationsvast reconstructive operations

with additional risk factors with additional risk factors

Prophylaxis of deep vein thrombosisProphylaxis of deep vein thrombosis

standard heparinstandard heparin

low molecular weight heparinlow molecular weight heparin

FraxiparinFraxiparin 0,01ml/kg0,01ml/kg

ClexaneClexane 1 mg/ kg1 mg/ kg

Clivarin 1432Clivarin 1432 85jm/kg85jm/kg

fewer complicationsfewer complications

lower cost of treatmentlower cost of treatment

convenient way of administrationconvenient way of administration